Talk:Aflibercept

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Aflibercept.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Approvals

So there's details on a date of approval ofr use in DM/DMO, but not where. UK spelling of "oedema" so that suggests the EMA gave the thumbs up and the EC approved it -- but it could instead be the FDA's approval and date. Sucks not to be in the US or Europe though -- those places are irrelevant when it comes to this, it seems. — Preceding unsigned comment added by 213.107.159.3 (talk) 21:14, 27 August 2015 (UTC)[reply]

Cost

Aflibercept (Zaltrap) is so expensive that, at the urging of Peter Bach, Memorial-Sloan Kettering decided not to use it.

http://nymag.com/news/features/cancer-drugs-2013-10/ The Cost of Living New drugs could extend cancer patients’ lives—by days. At a cost of thousands and thousands of dollars. Prompting some doctors to refuse to use them. By Stephen S. Hall New York Magazine Oct 20, 2013 --Nbauman (talk) 16:45, 21 October 2013 (UTC)[reply]

ziv-aflibercept is cheaper (but slightly different formulation) - See Another Cancer Drug May Be Effective Bargain for DME Treatment which says/quotes ""Ziv-aflibercept, with its lower cost per injection, could be a potential cost-effective substitute for aflibercept (Eylea), in the same way that bevacizumab is a cost-effective substitute for ranibizumab (Lucentis)," Soheilian said. "It has the same molecular structure as aflibercept. Although they have differences in the preparation and drug formulation, these two are members of VEGF trap products, which act as soluble decoy receptors, neutralizing all VEGF-A isoforms."" - Rod57 (talk) 18:04, 17 November 2017 (UTC)[reply]

Can anybody elaborate follwoing wordings

"In 2017, injections of aflibercept (HCPCS code J0178) were responsible for the most billing to Medicare Part B, at $2.36 billion." How much was used for cancer treatment, and how much was used for eye treatment? Thanks. ThomasYehYeh (talk) 02:37, 30 December 2023 (UTC)[reply]